Expert Review — 2025 Guidelines

Pulmonary Aspergillosis
vs Mucormycosis

Side-by-side clinical comparison: risk factors, diagnosis, treatment, and prognosis

Aspergillus spp. Mucorales spp. Evidence-Based ATS · Chinese · BTS · ESCMID · IDSA
42%
IPA attributable mortality (HM)
40–80%
PM overall mortality
90%
IFI cases = IPA in hematologic malignancy
≥0.5
Serum GM index cutoff (probable IPA)
Clinical Comparison Matrix
Invasive Pulmonary Aspergillosis
Pulmonary Mucormycosis
Causative Organisms
A. fumigatus, A. niger, A. flavus, A. terreus
Rhizopus, Mucor, Absidia, Cunninghamella
Epidemiology
Most common IFI in HM/HSCT (up to 90% of IFI); global distribution
Rare (~500 cases/year US); increasing due to immunosuppression
Key Risk Factors
Neutropenia, HSCT, GVHD, prolonged high-dose steroids, SOT, AIDS
DKA (most distinctive), iron overload, neutropenia, voriconazole prophylaxis
Disease Onset
Days to weeks; gradual worsening typical
Days; rapidly progressive, fulminant course
Pathology
Angioinvasion → hemorrhage, thrombosis, necrosis, cavitation
Severe angioinvasion → extensive necrosis, tissue infarction, black eschar
Imaging Hallmark
nodular lesions, halo sign (early), air crescent sign (recovery)
Reverse halo (atoll sign), mass-like consolidation, pleural effusion
Galactomannan
POSITIVE — serum ≥ 0.5, BAL ≥ 1.0 (key diagnostic tool)
NEGATIVE — not useful (Mucorales lack GM)
1,3-β-D-Glucan
May be positive; sensitive but non-specific
May be positive; non-specific (not diagnostic)
First-Line Treatment
Voriconazole IV 6 mg/kg loading → 4 mg/kg q12h (ATS 2025)
L-AmB 5–10 mg/kg/day IV induction (Muthu 2026)
Alternatives
Isavuconazole (equally acceptable), L-AmB, posaconazole
Posaconazole or isavuconazole oral (maintenance/step-down)
Combination Therapy
Conditional recommendation: triazole + echinocandin for severe/refractory cases
Not routinely recommended; consider for severe/refractory disease
Surgery
Salvage / adjunctive; for hemoptysis, cavity, refractory disease
CRITICAL — early aggressive surgical debridement is essential for survival
TDM Required
YES — Voriconazole: trough 1–5.5 mg/L; Posaconazole: ≥ 1–1.5 mg/L
Posaconazole trough ≥ 1–1.5 mg/L; Isavuconazole: not routinely required
Overall Mortality
30–50% (HM/HSCT); < 20% (SOT); 72% (HSCT attributable)
40–80% overall; 90%+ if disseminated or untreated
Treatment Duration
Minimum 6–12 weeks; often longer based on immune reconstitution
6–12 months minimum; lifelong in chronic immunosuppression
Key Guidelines
ATS 2025, ESCMID-ECMM-ERS 2017, IDSA 2016, BTS 2025
Chinese Guidelines 2025, Muthu et al. 2026, ECIL-6
Treatment Overview

IPA — First-Line Therapy

  • Voriconazole IV: 6 mg/kg q12h × 1d → 4 mg/kg q12h
    PO: 200–300 mg q12h | Target trough 1–5.5 mg/L ATS 2025 — gold standard monotherapy
  • Isavuconazole 200 mg q8h × 6 doses → 200 mg q24h
    Equally acceptable alternative; fewer drug interactions
  • + Echinocandin (Conditional) For severe / refractory cases
    Micafungin 100–150 mg/d or Caspofungin 70→50 mg/d
  • Prophylaxis Posaconazole oral 200 mg q8h (preferred)
    Voriconazole as alternative; in HM/HSCT

PM — First-Line Therapy

  • L-AmB 5–10 mg/kg/day IV induction until stable
    Muthu et al. 2026 — cornerstone of PM therapy
  • Posaconazole Modified-release 300 mg q12h × 2 → 300 mg q24h
    Step-down maintenance; TDM target ≥ 1–1.5 mg/L
  • Isavuconazole 200 mg q8h × 6 → 200 mg q24h
    Alternative oral maintenance; fewer interactions
  • Host Optimization Glycemic control (DKA), reduce immunosuppression, iron chelation (deferasirox)
    As critical as antifungal therapy itself